New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
16:22 EDTLMCA, ULTA, GMCR, ARO, SIRI, CELG, SBUXOn The Fly: Closing Wrap
Stocks on Wall Street were lower following another session dominated by headlines concerning the geopolitical situation. Stocks were lower early in the session following the lower than expected University of Michigan consumer confidence reading. The market moved in a narrow range and crossed back and forth across the flat-line several times. Investors remain on edge following several recent poor economic reports out of China and frequent remainders of the upcoming elections in the Ukraine on Sunday. ECONOMIC EVENTS: In the U.S., producer prices fell 0.1% overall in February, versus an expected increase of 0.2%. The core reading, which excludes food and energy, fell 0.2%, versus an expected increase of 0.1%. The Reuters/University of Michigan Consumer Sentiment Survey for March unexpectedly dropped to a four-month low of 79.9. The preliminary reading for the month was expected by analysts to have come in at 81.8, which would have been a slight bump from the prior 81.6 figure. In Europe, citizens of the Crimea region of the Ukraine are likely to vote to secede this weekend, even as Ukraine, the U.S and the European Union maintain that the vote is illegal. U.S. Secretary of State John Kerry said he was told that Vladimir Putin is not prepared to make any decision regarding Ukraine until after the country's referendum. COMPANY NEWS: Liberty Media (LMCA) shares gained $9.11, or 7.22%, to $135.25 after the company announced last night that it plans to reclassify its common stock into two tracking stocks, one called Liberty Media Group and the other called Liberty Broadband Group. Liberty President & CEO Greg Maffei called the move "another step in Liberty’s process of offering investors greater choice, transparency and focus." Liberty said in conjunction with the plan that it would drop plans to buy the rest of Sirius XM (SIRI), in which it currently holds a 53% stake in. Sirius XM had previously suspended its stock repurchase program in connection with Liberty Media's proposal and it announced today that it now intends to resume the repurchase plan. Shares of Sirius advanced 7c, or 2.08%, to $3.44 following the news. MAJOR MOVERS: Among the notable gainers was beauty retailer Ulta Salon (ULTA), which advanced $5.75, or 6.42%, to $95.26 after the company’s fourth quarter results beat estimates. Also higher were shares of single-serve coffee machine maker Keurig Green Mountain (GMCR), which rose $7.09, or 6.68%, to $113.25 after the company agreed to new terms in its deal with coffee giant Starbucks (SBUX). Among the noteworthy losers was teen retailer Aeropostale (ARO), which dropped $1.47, or 20.14%, to $5.83 after its fourth quarter results and first quarter outlook missed analysts' consensus expectations and the company entered a financing deal with private equity firm Sycamore Partners. Also lower were shares of drug maker Celgene (CELG), which dropped $6.59, or 4.22%, to $149.41 after the U.K.'s healthcare guidance body issued new draft guidance on the use of the company's Revlimid drug. INDEXES: The Dow fell 43.22, or 0.27%, to 16,065.67, the Nasdaq dropped 15.02, or 0.35%, to 4,245.40, and the S&P 500 declined 5.21, or 0.28%, to 1,841.13.
News For LMCA;SIRI;GMCR;SBUX;ARO;ULTA;CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
January 15, 2015
06:21 EDTULTAUlta Salon upgraded to Outperform from Perform at Oppenheimer
January 13, 2015
16:00 EDTCELGOptions Update; January 13, 2015
iPath S&P 500 VIX Short-Term Futures up 66c to 34.42. Option volume leaders: AAPL JNJ CELG WFM TSLA TWTR AMZN GILD according to Track Data.
12:48 EDTCELGOn The Fly: Midday Wrap
Subscribe for More Information
09:36 EDTCELGActive equity options trading
Active equity options trading according to Track Data: AAPL AMD AA TWTR GILD C CELG TSLA GOOG
09:00 EDTSIRILiberty Media and Sirius XM mentioned positively at Morgan Stanley
Subscribe for More Information
07:43 EDTCELGCelgene price target raised to $142 from $109 at Bernstein
Subscribe for More Information
07:24 EDTCELGCelgene 2015 guidance conservative, says Cantor
Subscribe for More Information
January 12, 2015
16:12 EDTCELGAgios announces Celgene agrees to exercise option to license AG-120
Agios Pharmaceuticals (AGIO) announced that its collaboration partner Celgene (CELG) has agreed that it will exercise its option to obtain an exclusive license outside the United States for AG-120, a first-in-class, oral, potent inhibitor of the mutant IDH1 protein under the terms of the 2010 collaboration agreement. This would be the second IDH mutant inhibitor to be licensed by Celgene in less than a year. AG-120 is currently being evaluated in two Phase 1 dose escalation trials, one in advanced hematologic malignancies and the other in advanced solid tumors. Both trials are evaluating AG-120 in patients whose cancer harbors an IDH1 mutation. The first data from the AG-120 program were presented at the EORTC-NCI-AACR Symposium on November 19, 2014 in advanced hematologic malignancies. Agios expects to report the first data from the Phase 1 advanced solid tumor trial at a medical conference in 2015. Celgene's exercise of the option is subject to receipt of any required regulatory approvals including any applicable clearance under the Hart-Scott-Rodino Act.
16:00 EDTSIRIOptions Update; January 12, 2015
iPath S&P 500 VIX Short-Term Futures up 1.57 to 33.54. Option volume leaders: AAPL TSLA TWTR AMZN AA SIRI RIG FRO C according to Track Data.
12:10 EDTCELGRBC Capital says Celgene's shares could rise to $200 'over time'
The long-term profit guidance that Celgene (CELG) released today suggests that the stock, currently trading around $115, could reach $200 "over time," RBC Capital wrote in a note to investors today. WHAT'S NEW: After Celgene estimated that its EPS would exceed $12.50, excluding certain items, by 2020, RBC Capital says that the guidance exceeded the firm's previous outlook. RBC added that Celgene's projection increases its confidence in the predictability of the drug maker's performance over the longer term. The firm recommended that investors own Celgene in 2015, noting that the company has the potential to settle its patent case with Actavis (ACT). A settlement would enable investors to focus on Celgene's visible long-term growth and the robust opportunity provided by its drugs in development, RBC stated. Historically, investors have not given Celgene credit for these strengths, the firm stated. PRICE ACTION: In early afternoon trading, Celgene rose 1.5% to $115.35.
11:09 EDTCELGCelgene sees 2020 adjusted EPS over $12.50, sales above $20B
Subscribe for More Information
11:06 EDTCELGCelgene backs FY17 target for adjusted EPS $7.50, sales $13B-$14B
Subscribe for More Information
11:03 EDTCELGCelgene sees FY15 Revlimid sales $5.6B-$5.7B
Subscribe for More Information
11:02 EDTCELGCelgene sees Q4 adjusted EPS $1.01, consensus 99c
Subscribe for More Information
11:02 EDTCELGCelgene sees FY14 adjusted EPS $3.71, consensus $3.69
Sees FY14 net product sales $7.56B, consensus $7.66B. Sees FY14 Revlimid sales $4.98B, Abraxane sales $848M, Pomalyst/Imnovid sales $680M and Otezla sales $70M.
10:59 EDTCELGCelgene sees FY15 adjusted EPS $4.60-$4.75, consensus $4.84
Subscribe for More Information
10:56 EDTCELGCelgene says no higher priority that accelerating development of Crohn's drug
Subscribe for More Information
10:53 EDTCELGCelgene says Otezla scripts accelerated in Q4
10:51 EDTCELGCelgene reports FY14 EPS $3.71, consensus $3.69
Subscribe for More Information
10:44 EDTCELGCelgene CEO says company expects to meet, exceed 2017 guidance
The company is speaking at JPMorgan's conference.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use